OncoPan®: An NGS-Based Screening Methodology to Identify Molecular Markers for Therapy and Risk Assessment in Pancreatic Ductal Adenocarcinoma
暂无分享,去创建一个
V. Pensotti | M. Pierotti | F. Sessa | M. Tibiletti | S. Volorio | P. Mariani | A. Chiaravalli | F. Mariette | S. Fortuzzi | I. Carnevali | S. Facchi | Stefano Fortuzzi
[1] F. Jiao,et al. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer , 2022, EBioMedicine.
[2] Koji Tanaka,et al. HER2-positive adenocarcinoma arising from heterotopic pancreas tissue in the duodenum: A case report , 2021, World journal of gastroenterology.
[3] C. Iacobuzio-Donahue,et al. Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. , 2021, Journal of the National Cancer Institute.
[4] Yanlin Huang,et al. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer , 2021, BMC cancer.
[5] M. Reni,et al. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort , 2021, ESMO open.
[6] C. Cella,et al. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. , 2019, Cancer treatment reviews.
[7] Walter G. Park,et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium , 2019, Gut.
[8] F. Sessa,et al. Universal screening to identify Lynch syndrome: two years of experience in a Northern Italian Center , 2019, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[9] Joon-Oh Park,et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.
[10] A. Lucas,et al. Familial Pancreatic Ductal Adenocarcinoma. , 2019, The American journal of pathology.
[11] E. Petricoin,et al. Molecular Profiling of Pancreatic Cancer Patients—Response , 2018, Clinical Cancer Research.
[12] L. Neumayer,et al. Pancreatic cancer as a sentinel for hereditary cancer predisposition , 2018, BMC Cancer.
[13] John M S Bartlett,et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.
[14] L. Terracciano,et al. Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance , 2018, Clinical Cancer Research.
[15] J. Cicenas,et al. JNK, p38, ERK, and SGK1 Inhibitors in Cancer , 2017, Cancers.
[16] M. Kloor,et al. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer , 2017, Cold Spring Harbor molecular case studies.
[17] Steven J. M. Jones,et al. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.
[18] S. Kakar,et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Kakar,et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. , 2016, Archives of pathology & laboratory medicine.
[20] Raymond Dalgleish,et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update , 2016, Human mutation.
[21] A. Vanoli,et al. TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer , 2016, Virchows Archiv.
[22] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[23] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[24] J. Kench,et al. Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.
[25] P. Queirolo,et al. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families , 2012, Journal of Medical Genetics.
[26] P. Scardino,et al. Susceptibility Loci Associated with Prostate Cancer Progression and Mortality , 2010, Clinical Cancer Research.
[27] Changanamkandath Rajesh,et al. Functional characterization of the RAD51D E233G genetic variant , 2009, Pharmacogenetics and genomics.
[28] M. J. van de Vijver,et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.